HRP20100012T1 - Kombinacije koje sadrže epotilone i inhibitore protein-tirozin-kinaze i njihova farmaceutska uporaba - Google Patents

Kombinacije koje sadrže epotilone i inhibitore protein-tirozin-kinaze i njihova farmaceutska uporaba Download PDF

Info

Publication number
HRP20100012T1
HRP20100012T1 HR20100012T HRP20100012T HRP20100012T1 HR P20100012 T1 HRP20100012 T1 HR P20100012T1 HR 20100012 T HR20100012 T HR 20100012T HR P20100012 T HRP20100012 T HR P20100012T HR P20100012 T1 HRP20100012 T1 HR P20100012T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
lower alkyl
acceptable salt
combination according
formula
Prior art date
Application number
HR20100012T
Other languages
English (en)
Croatian (hr)
Inventor
Min-Jian Huang Jerry
Ranganathan Johri Anandhi
Richard Linnartz Ronald
M. J. Mcsheehy Paul
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20100012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20100012T1 publication Critical patent/HRP20100012T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20100012T 2004-11-30 2005-11-28 Kombinacije koje sadrže epotilone i inhibitore protein-tirozin-kinaze i njihova farmaceutska uporaba HRP20100012T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30
PCT/US2005/042975 WO2006060331A1 (en) 2004-11-30 2005-11-28 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
HRP20100012T1 true HRP20100012T1 (hr) 2010-02-28

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100012T HRP20100012T1 (hr) 2004-11-30 2005-11-28 Kombinacije koje sadrže epotilone i inhibitore protein-tirozin-kinaze i njihova farmaceutska uporaba

Country Status (28)

Country Link
US (2) US20080139587A1 (da)
EP (1) EP1819331B1 (da)
JP (1) JP2008521826A (da)
KR (1) KR20070088653A (da)
CN (1) CN101065127A (da)
AT (1) ATE445398T1 (da)
AU (1) AU2005312061B2 (da)
BR (1) BRPI0518733A2 (da)
CA (1) CA2584163A1 (da)
CY (1) CY1110559T1 (da)
DE (1) DE602005017181D1 (da)
DK (1) DK1819331T3 (da)
ES (1) ES2333348T3 (da)
HR (1) HRP20100012T1 (da)
IL (1) IL183138A (da)
JO (1) JO2596B1 (da)
MA (1) MA29032B1 (da)
MX (1) MX2007006371A (da)
NO (1) NO20073370L (da)
NZ (1) NZ554552A (da)
PL (1) PL1819331T3 (da)
PT (1) PT1819331E (da)
RU (1) RU2423980C2 (da)
SI (1) SI1819331T1 (da)
TN (1) TNSN07212A1 (da)
TW (1) TW200630091A (da)
WO (1) WO2006060331A1 (da)
ZA (1) ZA200703196B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2014025395A1 (en) 2012-08-06 2014-02-13 Duke University Compounds and methods for targeting hsp90
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
US11261187B2 (en) 2016-04-22 2022-03-01 Duke University Compounds and methods for targeting HSP90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
US12220423B2 (en) 2018-07-24 2025-02-11 Hygia Pharmaceuticals, Llc Compounds, derivatives, and analogs for cancer
WO2021185844A1 (en) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021233534A1 (en) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
CN115768890A (zh) 2020-04-15 2023-03-07 加州理工学院 通过分子和物理启动对t细胞免疫疗法的热控制
EP4192509A1 (en) 2020-08-05 2023-06-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022047259A1 (en) 2020-08-28 2022-03-03 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
CN119816589A (zh) 2022-08-02 2025-04-11 国立大学法人北海道大学 使用细胞器复合体改善细胞疗法的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
EP1169038B9 (en) * 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
RU2313345C2 (ru) * 2001-02-27 2007-12-27 Новартис Аг Комбинации, содержащие ингибитор трансдукции сигнала и производное эпотилона
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
CN101816792A (zh) * 2002-06-10 2010-09-01 诺瓦提斯公司 包含埃坡霉素的组合及其药学用途
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
GB0215844D0 (en) * 2002-07-09 2002-08-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2007124492A (ru) 2009-04-10
DE602005017181D1 (de) 2009-11-26
HK1109059A1 (en) 2008-05-30
EP1819331A1 (en) 2007-08-22
US20110190312A1 (en) 2011-08-04
AU2005312061A1 (en) 2006-06-08
US20080139587A1 (en) 2008-06-12
RU2423980C2 (ru) 2011-07-20
MA29032B1 (fr) 2007-11-01
WO2006060331A1 (en) 2006-06-08
KR20070088653A (ko) 2007-08-29
PT1819331E (pt) 2009-11-30
JO2596B1 (en) 2011-02-27
DK1819331T3 (da) 2010-01-04
CY1110559T1 (el) 2015-04-29
PL1819331T3 (pl) 2010-03-31
TW200630091A (en) 2006-09-01
MX2007006371A (es) 2007-06-20
IL183138A0 (en) 2008-04-13
AU2005312061B2 (en) 2009-09-03
JP2008521826A (ja) 2008-06-26
ATE445398T1 (de) 2009-10-15
TNSN07212A1 (en) 2008-11-21
CN101065127A (zh) 2007-10-31
ES2333348T3 (es) 2010-02-19
NO20073370L (no) 2007-06-29
CA2584163A1 (en) 2006-06-08
EP1819331B1 (en) 2009-10-14
IL183138A (en) 2011-03-31
SI1819331T1 (sl) 2010-02-26
ZA200703196B (en) 2009-08-26
NZ554552A (en) 2011-05-27
BRPI0518733A2 (pt) 2008-12-02

Similar Documents

Publication Publication Date Title
HRP20100012T1 (hr) Kombinacije koje sadrže epotilone i inhibitore protein-tirozin-kinaze i njihova farmaceutska uporaba
NZ598907A (en) Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
MA32341B1 (fr) Dérivés de 3h- [1, 2, 3] triazolo [4, 5, d] pyrimidine, leur utilisation comme inhibiteurs de la kinase mtor et de la kinase pi3, et leurs synthèses
WO2007095223A3 (en) Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
WO2011113802A3 (en) Imidazopyridine and purine compounds, compositions and methods of use
WO2007120752A3 (en) 4, 5-dihydro- [1, 2, 4] triazolo [4, 3-f] pteridines as protein kinase plk1 inhibitors for the treatment of proliferative disorders
MY146474A (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
HRP20170162T1 (hr) HETEROARIL SUPSTITUIRANI PIROLO[2,3-b]PIRIDINI I PIROLO[2,3-b]PIRIMIDINI KAO INHIBITORI JANUS KINAZE
MX337817B (es) Pirazolo [1,5-a] pirimidinas de utilidad como inhibidores de proteina quinasas.
MX2009006700A (es) Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
MX2010003927A (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b.
NO2016021I1 (no) 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2Hpyrido[2,3-D]pyrimidinderivater og relaterte forbindelser for behandling av kreft
GEP20115147B (en) Pyrimidine derivatives used as pi-3 kinase inhibitors
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
NZ578876A (en) 3-amino-pyrrolo[3,4-c]pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
EA201170520A1 (ru) Ингибитор p38 mapk-киназы
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
SE0400284D0 (sv) Novel compounds
WO2008070313A3 (en) 3-(dihydro-1h-pyrazolo [4,3-d] pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
MX2007009372A (es) Nuevos compuestos ii derivados de 2-piridina como inhibidores de elastasa neutrofila.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2006116733A3 (en) Protein kinase inhibitors